Company Description
Hong Kong Pharma Digital Technology's offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance.
Through our engagement with OTC pharmaceutical suppliers, logistics companies, and merchants who operate stores on Chinese e-commerce platforms, Joint Cross Border offers a convenient one-stop solution for Mainland Chinese customers who wish to access OTC pharmaceutical products outside Mainland China.
Joint Cross Border’s offering includes a comprehensive array of services, such as pre-consultation, product information review, procuring overseas OTC pharmaceutical products, enlisting OTC pharmaceutical products to the Hong Kong Department of Health, obtaining import and export permits and clearances, storing products at warehouses, packaging, and arranging for logistics and end-to-end delivery services for consumers.
| Country | Hong Kong |
| Founded | 2016 |
| Industry | Integrated Freight & Logistics |
| Sector | Industrials |
| Employees | 19 |
| CEO | Lap Sun Wong |
Contact Details
Address: Room B1, 5/F., Well Town Industrial Building, 13 Ko Fai Road Yau Tong, Kowloon Hong Kong | |
| Phone | +852 2618-9289 |
| Website | 9zt.hk |
Stock Details
| Ticker Symbol | HKPD |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0002007702 |
| SIC Code | 5122 |
Key Executives
| Name | Position |
|---|---|
| Lap Sun Wong | Chief Executive Officer and Chairman of the Board of Directors |
| Zhifang Zhang | Director |
| Man Bun Kwok | Chief Financial Officer |
| Yingying Li | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | EFFECT | Notice of Effectiveness |
| Dec 10, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Nov 27, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Nov 22, 2024 | FWP | Free Writing Prospectus |
| Nov 21, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Oct 29, 2024 | F-1 | Registration statement for certain foreign private issuers |
| Oct 4, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Sep 23, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Aug 22, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jun 28, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |